Publications dans lesquelles il/elle collabore avec Rubén Pío Osés (110)

2024

  1. Elevated expression of complement factor I in lung cancer cells associates with shorter survival–Potentially via non-canonical mechanism

    Translational Research, Vol. 269, pp. 1-13

  2. Fasting and fasting-mimicking conditions in the cancer immunotherapy era

    Journal of Physiology and Biochemistry

  3. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

    Molecular Cancer, Vol. 23, Núm. 1

  4. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

    eBioMedicine, Vol. 102

2023

  1. Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer

    EMBO Reports, Vol. 24, Núm. 8

2022

  1. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d

    Frontiers in Immunology, Vol. 13

  2. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

  3. Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood

    Bioengineering and Translational Medicine, Vol. 7, Núm. 3

  4. The complement system as a regulator of tumor-promoting activities mediated by myeloid-derived suppressor cells

    Cancer Letters, Vol. 549

  5. Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer

    Cancer Discovery, Vol. 12, Núm. 5, pp. 1356-1377

  6. Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 1

2021

  1. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer

    Translational Research, Vol. 233, pp. 77-91

  2. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

  3. Molecular biomarkers in early stage lung cancer

    Translational Lung Cancer Research, Vol. 10, Núm. 2, pp. 1165-1185

  4. Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge

    Frontiers in Immunology, Vol. 12

  5. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

  6. Surgical Outcomes in a Lung Cancer-Screening Program Using Low Dose Computed Tomography

    Archivos de Bronconeumologia, Vol. 57, Núm. 2, pp. 101-106

  7. The complement system in ovarian cancer: An underexplored old path

    Cancers, Vol. 13, Núm. 15

  8. Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma

    Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337

2020

  1. Drugsniper, a tool to exploit loss-of-function screens, identifies CREBBP as a predictive biomarker of VOLASERTIB in small cell lung carcinoma (SCLC)

    Cancers, Vol. 12, Núm. 7, pp. 1-18